OCC - Orthocell reports 98.6% success rate in Striate+(TM) dental membrane study
(NewsDirect)
Orthocell Ltd (ASX:OCC, OTC:ORHHF) CEO and managing director PaulAnderson joins Jonathan Jackson in the Proactive studio to talkthrough a 98.6% success rate in a post-market clinical study examiningthe effectiveness of its Striate+™ dental membrane in guided boneregeneration for dental implants. The Striate+™, a resorbablecollagen membrane, has been validated through this study as a leadingsolution in bone and tissue regeneration, supporting Orthocell’sclaim of its product being the best choice for such medicalprocedures. Anderson highlights the membrane's ability to enablehigh-quality bone and tissue repair, crucial for functional andaesthetically pleasing outcomes in patients. These results, indicatinga notable level of bone formation and stability, were obtained from 99patients, reinforcing the product's efficacy in real-worldapplications. Orthocell anticipates that the success of theStriate+™ will enhance its visibility among dental professionals andsupport BioHorizons, its exclusive global distributor, in increasingthe product's market adoption. This development is particularlysignificant given the estimated annual market potential of more thanUS$700 million for the Striate+ product. The findings are scheduledfor presentation at the European Association for Osseintegration (EAO)annual meeting in October 2024. The study also contributes to theclinical data needed for re-certification of EU market approval underthe new European Medical Device Regulations (MDR), following anearlier Post-Market Clinical Follow-up (PMCF) study.
ContactDetails
Proactive Investors
JonathanJackson
+61 413 713 744
jonathan@proactiveinvestors.com
Copyright (c) 2024 TheNewswire - All rights reserved.